Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Healthcare Biotechnology
Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Trillium Therapeutics Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Comment by bigwalleyeon Jun 25, 2010 1:18pm
597 Views
Post# 17222185

RE: My News take

RE: My News takeAdd to this this company does not have a CEO after June 30th. Plus, yes they are going to try and sell the farm

As part of this program, the employment contracts for each of the senior officers of the Company (CEO, CFO, VP Product, Development and VP, Commercial Planning) have been terminated effective June 30, 2010. Alan Moore, the current CEO, and Barry Herring, the current CFO have agreed to stay on with the Company in their current capacities on a consulting basis for the following six months to assist the Company in its attempt to maximize the value of its intellectual property.

good luck all
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities